BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1422 related articles for article (PubMed ID: 28950145)

  • 21. Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer.
    Al-Shibli KI; Donnem T; Al-Saad S; Persson M; Bremnes RM; Busund LT
    Clin Cancer Res; 2008 Aug; 14(16):5220-7. PubMed ID: 18698040
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Low PD-1 Expression in Cytotoxic CD8
    Mazzaschi G; Madeddu D; Falco A; Bocchialini G; Goldoni M; Sogni F; Armani G; Lagrasta CA; Lorusso B; Mangiaracina C; Vilella R; Frati C; Alfieri R; Ampollini L; Veneziani M; Silini EM; Ardizzoni A; Urbanek K; Aversa F; Quaini F; Tiseo M
    Clin Cancer Res; 2018 Jan; 24(2):407-419. PubMed ID: 29074606
    [No Abstract]   [Full Text] [Related]  

  • 23. Clinicopathologic Features and Immune Microenvironment of Non-Small-cell Lung Cancer With Primary Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.
    Takashima Y; Sakakibara-Konishi J; Hatanaka Y; Hatanaka KC; Ohhara Y; Oizumi S; Hida Y; Kaga K; Kinoshita I; Dosaka-Akita H; Matsuno Y; Nishimura M
    Clin Lung Cancer; 2018 Jul; 19(4):352-359.e1. PubMed ID: 29544718
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tumor-infiltrating Foxp3+ regulatory T cells are correlated with cyclooxygenase-2 expression and are associated with recurrence in resected non-small cell lung cancer.
    Shimizu K; Nakata M; Hirami Y; Yukawa T; Maeda A; Tanemoto K
    J Thorac Oncol; 2010 May; 5(5):585-90. PubMed ID: 20234320
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy.
    Tokito T; Azuma K; Kawahara A; Ishii H; Yamada K; Matsuo N; Kinoshita T; Mizukami N; Ono H; Kage M; Hoshino T
    Eur J Cancer; 2016 Mar; 55():7-14. PubMed ID: 26771872
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Link between tumor-promoting fibrous microenvironment and an immunosuppressive microenvironment in stage I lung adenocarcinoma.
    Sakai T; Aokage K; Neri S; Nakamura H; Nomura S; Tane K; Miyoshi T; Sugano M; Kojima M; Fujii S; Kuwata T; Ochiai A; Iyoda A; Tsuboi M; Ishii G
    Lung Cancer; 2018 Dec; 126():64-71. PubMed ID: 30527194
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characterization of the tumor immune-microenvironment of lung adenocarcinoma associated with usual interstitial pneumonia.
    Ueda T; Aokage K; Mimaki S; Tane K; Miyoshi T; Sugano M; Kojima M; Fujii S; Kuwata T; Ochiai A; Kusumoto M; Suzuki K; Tsuchihara K; Nishikawa H; Goto K; Tsuboi M; Ishii G
    Lung Cancer; 2018 Dec; 126():162-169. PubMed ID: 30527182
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical impact of immune microenvironment in stage I lung adenocarcinoma: tumor interleukin-12 receptor β2 (IL-12Rβ2), IL-7R, and stromal FoxP3/CD3 ratio are independent predictors of recurrence.
    Suzuki K; Kadota K; Sima CS; Nitadori J; Rusch VW; Travis WD; Sadelain M; Adusumilli PS
    J Clin Oncol; 2013 Feb; 31(4):490-8. PubMed ID: 23269987
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impaired Tumor-Infiltrating T Cells in Patients with Chronic Obstructive Pulmonary Disease Impact Lung Cancer Response to PD-1 Blockade.
    Biton J; Ouakrim H; Dechartres A; Alifano M; Mansuet-Lupo A; Si H; Halpin R; Creasy T; Bantsimba-Malanda C; Arrondeau J; Goldwasser F; Boudou-Rouquette P; Fournel L; Roche N; Burgel PR; Goc J; Devi-Marulkar P; Germain C; Dieu-Nosjean MC; Cremer I; Herbst R; Damotte D
    Am J Respir Crit Care Med; 2018 Oct; 198(7):928-940. PubMed ID: 29518341
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immune Microenvironment Differences Between Squamous and Non-squamous Non-small-cell Lung Cancer and Their Influence on the Prognosis.
    Meng X; Gao Y; Yang L; Jing H; Teng F; Huang Z; Xing L
    Clin Lung Cancer; 2019 Jan; 20(1):48-58. PubMed ID: 30341017
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CD4/CD8 + T cells, DC subsets, Foxp3, and IDO expression are predictive indictors of gastric cancer prognosis.
    Li F; Sun Y; Huang J; Xu W; Liu J; Yuan Z
    Cancer Med; 2019 Dec; 8(17):7330-7344. PubMed ID: 31631566
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association of PD-L1 expression and PD-L1 gene polymorphism with poor prognosis in lung adenocarcinoma and squamous cell carcinoma.
    Yeo MK; Choi SY; Seong IO; Suh KS; Kim JM; Kim KH
    Hum Pathol; 2017 Oct; 68():103-111. PubMed ID: 28851662
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Predominant infiltration of macrophages and CD8(+) T Cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer.
    Kawai O; Ishii G; Kubota K; Murata Y; Naito Y; Mizuno T; Aokage K; Saijo N; Nishiwaki Y; Gemma A; Kudoh S; Ochiai A
    Cancer; 2008 Sep; 113(6):1387-95. PubMed ID: 18671239
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CD4+CXCR4highCD69+ T cells accumulate in lung adenocarcinoma.
    Wald O; Izhar U; Amir G; Avniel S; Bar-Shavit Y; Wald H; Weiss ID; Galun E; Peled A
    J Immunol; 2006 Nov; 177(10):6983-90. PubMed ID: 17082613
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Regulatory T cells and their prognostic value in hepatopancreatobiliary tumours.
    Ozgur HH; Ercetin AP; Eliyatkin N; Seren A; Kupelioglu A; Ortac R; Diniz G; Aktas S
    Hepatogastroenterology; 2014 Oct; 61(135):1847-51. PubMed ID: 25713876
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Density of tumor-infiltrating FOXP3+ T cells as a response marker for induction chemoradiotherapy and a potential prognostic factor in patients treated with trimodality therapy for locally advanced non-small cell lung cancer.
    Tao H; Shien K; Soh J; Matsuda E; Toyooka S; Okabe K; Miyoshi S
    Ann Thorac Cardiovasc Surg; 2014; 20(6):980-6. PubMed ID: 24583705
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The implications of clinical risk factors, CAR index, and compositional changes of immune cells on hyperprogressive disease in non-small cell lung cancer patients receiving immunotherapy.
    Kim SR; Chun SH; Kim JR; Kim SY; Seo JY; Jung CK; Gil BM; Kim JO; Ko YH; Woo IS; Shim BY; Hong SH; Kang JH
    BMC Cancer; 2021 Jan; 21(1):19. PubMed ID: 33402127
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CD8
    Huang B; Liu R; Wang P; Yuan Z; Yang J; Xiong H; Zhang N; Huang Q; Fu X; Sun W; Li L
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32606053
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic Relevance of the Relative Presence of CD4, CD8 and CD20 Expressing Tumor Infiltrating Lymphocytes in Operable Non-small Cell Lung Cancer Patients.
    Giatromanolaki A; Anestopoulos I; Panayiotidis MI; Mitrakas A; Pappa A; Koukourakis MI
    Anticancer Res; 2021 Aug; 41(8):3989-3995. PubMed ID: 34281863
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Programmed Death Ligand-1 (PD-L1) Expression in Either Tumor Cells or Tumor-Infiltrating Immune Cells Correlates With Solid and High-Grade Lung Adenocarcinomas.
    Driver BR; Miller RA; Miller T; Deavers M; Gorman B; Mody D; Ge Y; Barrios R; Bernicker E; Kim M; Cagle PT
    Arch Pathol Lab Med; 2017 Nov; 141(11):1529-1532. PubMed ID: 28829153
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 72.